Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Type 1 diabetes: what is the role of autoimmunity in β cell death?
Marc Y. Donath
Marc Y. Donath
Published October 17, 2022
Citation Information: J Clin Invest. 2022;132(20):e164460. https://doi.org/10.1172/JCI164460.
View: Text | PDF
Commentary Article has an altmetric score of 4

Type 1 diabetes: what is the role of autoimmunity in β cell death?

  • Text
  • PDF
Abstract

The current dogma of type 1 diabetes pathogenesis asserts that an autoimmune attack leads to the destruction of pancreatic β cells, with subsequent hyperglycemia. This dogma is based on islet autoantibodies emerging prior to the onset of type 1 diabetes. In this issue of the JCI, Warncke et al. report on their investigation of the development of hyperglycemia below the diabetes threshold as an early proxy of β cell demise. Surprisingly, they found that an elevation in blood glucose preceded the appearance of autoimmunity. This observation calls into question the importance of autoimmunity as the primary cause of β cell destruction and has implications for prevention and treatment in diabetes.

Authors

Marc Y. Donath

×

Total citations by year

Year: 2025 2024 2023 Total
Citations: 3 6 1 10
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (10)

Title and authors Publication Year
Developmental beta-cell death orchestrates the islet’s inflammatory milieu by regulating immune system crosstalk
Akhtar MN, Hnatiuk A, Delgadillo-Silva L, Geravandi S, Sameith K, Reinhardt S, Bernhardt K, Singh SP, Maedler K, Brusch L, Ninov N
The EMBO Journal 2025
Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK
Shalev A
Endocrinology 2025
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD
Endocrine Reviews 2025
S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects.
Ursino G, Lucibello G, Teixeira PDS, Höfler A, Veyrat-Durebex C, Odouard S, Visentin F, Galgano L, Somm E, Vianna CR, Widmer A, Jornayvaz FR, Boland A, Ramadori G, Coppari R
Science Advances 2024
TMEM219 regulates the transcription factor expression and proliferation of beta cells
D\u2019Addio F, Assi E, Maestroni A, Rossi G, Usuelli V, Petrazzuolo A, Nardini M, Loretelli C, Ben Nasr M, Fiorina P
Frontiers in Endocrinology 2024
Living with and managing type 1 diabetes in humanitarian settings: A qualitative synthesis of lived experience and stakeholder tacit knowledge
James O, Abbou-Abbas L, Vijayasingham L
2024
Estimation of Individual Positive Anti-Islet Autoantibodies from 3 Screen ICA Titer
Kawasaki E, Jinnouchi H, Maeda Y, Okada A, Kawai K
International journal of molecular sciences 2024
A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging
Jing G, Jo S, Shalev A
Frontiers in Endocrinology 2024
Evaluating the causal effects between Grave's disease and diabetes mellitus: a bidirectional Mendelian randomization study.
Zhang Y, Fu L
Frontiers in endocrinology 2024
PPARs at the crossroads of T cell differentiation and type 1 diabetes
Riaz F, Wei P, Pan F
Frontiers in immunology 2023

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 7 X users
19 readers on Mendeley
See more details